AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9665011 — intervention group
Group type: COMPARATOR
Intervention: Sandimmun (S)
Number of subjects: 42
Study 7547114 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptomatic treatment
Number of subjects: 0
Study 7547114 — intervention group
Group type: EXPERIMENTAL
Intervention: New therapeutic approaches
Number of subjects: 0
Study 2220722 — intervention group
Group type: EXPERIMENTAL
Intervention: Brown‐McHardy (BMH)
Number of subjects: 20
Study 2220722 — intervention group
Group type: COMPARATOR
Intervention: Microvasive Rigiflex (MVR)
Number of subjects: 20
Study 601870 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy with isoniazid and rifampicin
Number of subjects: 108
Study 601870 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy with isoniazid and ethambutol
Number of subjects: 108
Study 601870 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical intervention (excision or aspiration)
Number of subjects: 108
Study 601870 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall treatment progress
Number of subjects: 108
Study 7215718 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbenoxolone 150 mg/day for 6 months
Number of subjects: 24
Study 7215718 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 31585702 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking cessation medication prescription recommended by counselor
Number of subjects: 214
Study 31585702 — intervention group
Group type: EXPERIMENTAL
Intervention: Insurance status
Number of subjects: 214
Study 31585702 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of inpatient smoking cessation medication
Number of subjects: 214
Study 29985680 — intervention group
Group type: EXPERIMENTAL
Intervention: Brexpiprazole (2 and 4 mg/day)
Number of subjects: 0
Study 29985680 — intervention group
Group type: EXPERIMENTAL
Intervention: Brexpiprazole (long-term treatment)
Number of subjects: 0
Study 29985680 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 29985680 — intervention group
Group type: EXPERIMENTAL
Intervention: Brexpiprazole
Number of subjects: 0
Study 27087970 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute MRI management
Number of subjects: 16
Study 27087970 — intervention group
Group type: COMPARATOR
Intervention: Conventional management
Number of subjects: 16
Study 24516261 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternate day therapy with atorvastatin 10 mg and fenofibrate 160 mg
Number of subjects: 110
Study 24516261 — intervention group
Group type: COMPARATOR
Intervention: Daily therapy with atorvastatin 10 mg and fenofibrate 160 mg
Number of subjects: 110
Study 22545737 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy for adherence and depression (CBT-AD)
Number of subjects: 89
Study 22545737 — intervention group
Group type: COMPARATOR
Intervention: Enhanced treatment as usual (ETAU)
Number of subjects: 89
Study 21142446 — intervention group
Group type: EXPERIMENTAL
Intervention: HAART treatment interruption (TI)
Number of subjects: 0
Study 17940308 — intervention group
Group type: EXPERIMENTAL
Intervention: 100-kVp protocol
Number of subjects: 60
Study 17940308 — intervention group
Group type: COMPARATOR
Intervention: 120-kVp protocol
Number of subjects: 60
Study 15567883 — intervention group
Group type: EXPERIMENTAL
Intervention: Gentle mechanical pressure on the cervix using the vaginal speculum for 7 minutes after embryo transfer
Number of subjects: 639
Study 15567883 — intervention group
Group type: COMPARATOR
Intervention: No pressure applied on the cervix during embryo transfer
Number of subjects: 639
Study 12386638 — intervention group
Group type: EXPERIMENTAL
Intervention: Itraconazole
Number of subjects: 10
Study 12386638 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 10188604 — intervention group
Group type: EXPERIMENTAL
Intervention: Dorsal interossei
Number of subjects: 0
Study 10188604 — intervention group
Group type: EXPERIMENTAL
Intervention: Volar interossei
Number of subjects: 0
Study 10188604 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumbrical muscles
Number of subjects: 0
Study 10188604 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrinsic muscles in neuroprosthesis
Number of subjects: 0
Study 7581094 — intervention group
Group type: EXPERIMENTAL
Intervention: rhIL-6 therapy at 0.3 microgram/kg/day
Number of subjects: 20
Study 7581094 — intervention group
Group type: EXPERIMENTAL
Intervention: rhIL-6 therapy at 1 microgram/kg/day
Number of subjects: 20
Study 7581094 — intervention group
Group type: EXPERIMENTAL
Intervention: rhIL-6 therapy at 3 micrograms/kg/day
Number of subjects: 20
Study 7581094 — intervention group
Group type: EXPERIMENTAL
Intervention: rhIL-6 therapy (all doses)
Number of subjects: 20
Study 7581094 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximal tolerated dose of rhIL-6
Number of subjects: 20
Study 2179979 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose piracetam (24 g per day)
Number of subjects: 60
Study 2179979 — intervention group
Group type: COMPARATOR
Intervention: Low-dose piracetam (6 g per day)
Number of subjects: 60
Study 2179979 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 380251 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen sodium and naproxen
Number of subjects: 0
Study 380251 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 29757433 — intervention group
Group type: EXPERIMENTAL
Intervention: Useful Field of View training (UFOVt)
Number of subjects: 34
Study 29757433 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitively stimulating activities (CSA)
Number of subjects: 34
Study 29757433 — intervention group
Group type: COMPARATOR
Intervention: No-contact control (NC)
Number of subjects: 34
Study 30650479 — intervention group
Group type: EXPERIMENTAL
Intervention: Shenmai Injection (SI), 50 mL each time, once per day for 10 days
Number of subjects: 100
Study 30650479 — intervention group
Group type: COMPARATOR
Intervention: Control group (conventional drugs for CHD)
Number of subjects: 100
Study 26486191 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide 1.2 mg
Number of subjects: 40
Study 26486191 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 24755046 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-point cane
Number of subjects: 14
Study 24755046 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard walker (SW)
Number of subjects: 14
Study 24755046 — intervention group
Group type: EXPERIMENTAL
Intervention: Wheeled walker (WW)
Number of subjects: 14
Study 24755046 — intervention group
Group type: COMPARATOR
Intervention: Unassisted stair ascending and descending
Number of subjects: 14
Study 21138718 — intervention group
Group type: EXPERIMENTAL
Intervention: Team Resilience training workshop (three 2-hour sessions over 3 consecutive days)
Number of subjects: 235
Study 21138718 — intervention group
Group type: COMPARATOR
Intervention: Control stores (no intervention)
Number of subjects: 235
Study 18556221 — intervention group
Group type: EXPERIMENTAL
Intervention: SF-SACRAH (short form score for the assessment and quantification of chronic rheumatic affections of the hands)
Number of subjects: 247
Study 18556221 — intervention group
Group type: EXPERIMENTAL
Intervention: SF-SACRAH
Number of subjects: 247
Study 18074664 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole magnesium 40 mg once daily for 2 to 12 months
Number of subjects: 146
Study 15358033 — intervention group
Group type: EXPERIMENTAL
Intervention: NCX‐4016 800 mg twice a day
Number of subjects: 48
Study 15358033 — intervention group
Group type: EXPERIMENTAL
Intervention: NCX‐4016 800 mg twice a day plus aspirin 325 mg
Number of subjects: 48
Study 15358033 — intervention group
Group type: COMPARATOR
Intervention: Aspirin 325 mg
Number of subjects: 48
Study 15358033 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 12502003 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidirectional motion loci in THR patients
Number of subjects: 0
Study 12502003 — intervention group
Group type: COMPARATOR
Intervention: Normal hip joint range of motion
Number of subjects: 0
Study 10335027 — intervention group
Group type: EXPERIMENTAL
Intervention: spiramycin 3 MIU twice daily for 7 or 10 days
Number of subjects: 55
Study 10335027 — intervention group
Group type: COMPARATOR
Intervention: clarithromycin 500 mg twice daily for 7 or 10 days
Number of subjects: 55
Study 10335027 — intervention group
Group type: EXPERIMENTAL
Intervention: spiramycin
Number of subjects: 55
Study 10335027 — intervention group
Group type: COMPARATOR
Intervention: clarithromycin
Number of subjects: 55
Study 7666064 — intervention group
Group type: EXPERIMENTAL
Intervention: Lead II used most commonly with a single-channel system (66.3%)
Number of subjects: 882
Study 7666064 — intervention group
Group type: EXPERIMENTAL
Intervention: Lead II plus V1 (or MCL1) selected most often with dual-channel systems (62.4%)
Number of subjects: 882
Study 7666064 — intervention group
Group type: EXPERIMENTAL
Intervention: Modification of lead selection based on location of AMI reported by 20% of respondents
Number of subjects: 882
Study 7666064 — intervention group
Group type: EXPERIMENTAL
Intervention: Correct identification of classic ischemia, injury, and infarction by 43.3% of respondents
Number of subjects: 882
Study 7666064 — intervention group
Group type: EXPERIMENTAL
Intervention: Right precordial leads usage
Number of subjects: 882
Study 2474848 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mM oleic acid
Number of subjects: 6
Study 2474848 — intervention group
Group type: COMPARATOR
Intervention: 20 mM oleyl alcohol
Number of subjects: 6
Study 412615 — intervention group
Group type: EXPERIMENTAL
Intervention: 4% disodium cromoglycate (DSCG) nasal solution
Number of subjects: 39
Study 412615 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study 29482026 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose diuretic strategy (median furosemide dose of 320 mg)
Number of subjects: 0
Study 29482026 — intervention group
Group type: COMPARATOR
Intervention: Low-dose diuretic strategy (median furosemide dose of 840 mg)
Number of subjects: 0
Study 29482026 — intervention group
Group type: EXPERIMENTAL
Intervention: Cystatin C (biomarker of renal dysfunction)
Number of subjects: 0
Study 29482026 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose strategy in patients with eGFR below median
Number of subjects: 0
Study 29482026 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced fluid output, weight loss, and diuretic efficiency (DE)
Number of subjects: 0
Study 28352985 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabozantinib 100 mg qd
Number of subjects: 64
Study 28352985 — intervention group
Group type: COMPARATOR
Intervention: Cabozantinib 100 mg qd and Erlotinib 50 mg qd
Number of subjects: 64
Study 28352985 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabozantinib 100 mg qd and Erlotinib 50 mg qd (phase I MTD)
Number of subjects: 64
Study 26184340 — intervention group
Group type: EXPERIMENTAL
Intervention: Cereal labeled 'fruit sugar'
Number of subjects: 164
Study 26184340 — intervention group
Group type: COMPARATOR
Intervention: Cereal labeled 'sugar'
Number of subjects: 164
Study 22956398 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-port (SP) configuration
Number of subjects: 28
Study 22956398 — intervention group
Group type: COMPARATOR
Intervention: 2-port (TP) configuration
Number of subjects: 28
Study 22956398 — intervention group
Group type: EXPERIMENTAL
Intervention: Training with TP followed by SP
Number of subjects: 28
Study 22956398 — intervention group
Group type: EXPERIMENTAL
Intervention: Training with SP followed by TP
Number of subjects: 28
Study 20441725 — intervention group
Group type: EXPERIMENTAL
Intervention: Imaginal exposure therapy (3 to 5 sessions)
Number of subjects: 60
Study 20441725 — intervention group
Group type: COMPARATOR
Intervention: Educational sessions only (1 to 3 sessions)
Number of subjects: 60
Study 20441725 — intervention group
Group type: EXPERIMENTAL
Intervention: Imaginal exposure therapy
Number of subjects: 60
Study 20441725 — intervention group
Group type: EXPERIMENTAL
Intervention: Imaginal exposure therapy in subgroup with acute unscheduled cardiovascular events and high baseline PTSD symptoms
Number of subjects: 60
Study 18602616 — intervention group
Group type: EXPERIMENTAL
Intervention: Trained group (healthy partner trained to direct intention toward the cancer patient)
Number of subjects: 36
Study 18602616 — intervention group
Group type: EXPERIMENTAL
Intervention: Wait group (couples tested before the partner was trained)
Number of subjects: 36
Study 18602616 — intervention group
Group type: COMPARATOR
Intervention: Control group (14 healthy couples received no training)
Number of subjects: 36
Study 16387405 — intervention group
Group type: EXPERIMENTAL
Intervention: Gold bonder systems (two types)
Number of subjects: 0
Study 16387405 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceramic Ti bonder
Number of subjects: 0
Study 16387405 — intervention group
Group type: COMPARATOR
Intervention: Gold‐palladium PFM alloy
Number of subjects: 0
Study 14649340 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-blinded neuromuscular transmission monitoring with rocuronium infusion at 6 microg kg(‐1) min(‐1)
Number of subjects: 20
Study 14649340 — intervention group
Group type: COMPARATOR
Intervention: Blinded neuromuscular transmission monitoring with rocuronium infusion at 6 microg kg(‐1) min(‐1) (fixed rate)
Number of subjects: 20
Study 11011985 — intervention group
Group type: EXPERIMENTAL
Intervention: Morning administration of OROS systems
Number of subjects: 1243
Study 11011985 — intervention group
Group type: EXPERIMENTAL
Intervention: Night administration of OROS systems
Number of subjects: 1243
Study 11011985 — intervention group
Group type: COMPARATOR
Intervention: Comparison of OROS systems total transit time to intrinsic bowel movement pattern
Number of subjects: 1243
Study 8661630 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparin (LMWH)
Number of subjects: 105
Study 8661630 — intervention group
Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 105
Study 1505647 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine 80 mg/day
Number of subjects: 425
Study 1505647 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 425
Study 6650543 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine
Number of subjects: 62
Study 6650543 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study 31504329 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening program for anal cancer prevention
Number of subjects: 3111
Study 31504329 — intervention group
Group type: COMPARATOR
Intervention: Non-screening group
Number of subjects: 3111
Study 29510461 — intervention group
Group type: EXPERIMENTAL
Intervention: Mexiletine 150 mg twice daily
Number of subjects: 20
Study 29510461 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 27939406 — intervention group
Group type: EXPERIMENTAL
Intervention: Glutaraldehyde-modified allergen extracts administered via therapeutic vaccine adsorbed onto aluminium hydroxide
Number of subjects: 1855
Study 27939406 — intervention group
Group type: EXPERIMENTAL
Intervention: Glutaraldehyde-modified allergen extracts
Number of subjects: 1855
Study 26146015 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine (2.5 mg)
Number of subjects: 6
Study 26146015 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine (25 mg)
Number of subjects: 6
Study 26146015 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 26146015 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine and Quetiapine
Number of subjects: 6
Study 23759449 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure and ritual prevention
Number of subjects: 111
Study 23759449 — intervention group
Group type: COMPARATOR
Intervention: Stress management training
Number of subjects: 111
Study 21349452 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel-eluting balloon (PEB)
Number of subjects: 50
Study 21349452 — intervention group
Group type: COMPARATOR
Intervention: Conventional balloon angioplasty (BA)
Number of subjects: 50
Study 19047719 — intervention group
Group type: EXPERIMENTAL
Intervention: Medial tibial slope in female subjects
Number of subjects: 55
Study 19047719 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral tibial slope in female subjects
Number of subjects: 55
Study 19047719 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronal tibial slope in female subjects
Number of subjects: 55
Study 19047719 — intervention group
Group type: EXPERIMENTAL
Intervention: Within-subject differences between medial and lateral tibial slopes
Number of subjects: 55
Study 19047719 — intervention group
Group type: EXPERIMENTAL
Intervention: Medial tibial plateau depth
Number of subjects: 55
Study 19047719 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation between slopes and age
Number of subjects: 55
Study 16572265 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron (12 mg, oral)
Number of subjects: 0
Study 16572265 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 14598426 — intervention group
Group type: EXPERIMENTAL
Intervention: Stenting
Number of subjects: 61
Study 14598426 — intervention group
Group type: COMPARATOR
Intervention: Emergency Surgery
Number of subjects: 61
Study 11908370 — intervention group
Group type: EXPERIMENTAL
Intervention: Colgate Actibrush (battery-powered toothbrush)
Number of subjects: 63
Study 11908370 — intervention group
Group type: COMPARATOR
Intervention: ADA-provided manual toothbrush (control)
Number of subjects: 63
Study 11908370 — intervention group
Group type: EXPERIMENTAL
Intervention: Colgate Actibrush
Number of subjects: 63
Study 8766415 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril (10 mg t.i.d.)
Number of subjects: 16
Study 8766415 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril plus Aspirin (325 mg/day)
Number of subjects: 16
Study 8766415 — intervention group
Group type: COMPARATOR
Intervention: Aspirin alone
Number of subjects: 16
Study 8766415 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 16
Study 8766415 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril plus Aspirin
Number of subjects: 16
Study 8766415 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 7893494 — intervention group
Group type: EXPERIMENTAL
Intervention: Warm retrograde blood cardioplegia (WRC) with Fremes solution (initially antegrade and retrograde high potassium solution, then continuous retrograde low potassium solution)
Number of subjects: 60
Study 7893494 — intervention group
Group type: COMPARATOR
Intervention: Intermittent oxygenated cold Fresenius solution antegrade and retrograde (FR)
Number of subjects: 60
Study 3299089 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 mg of AZT every four hours for 24 weeks
Number of subjects: 282
Study 3299089 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 282
Study 29317123 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline serum high‐sensitivity C‐reactive protein (hsCRP) values <10 mg/L categorized into tertiles
Number of subjects: 572
Study 27716324 — intervention group
Group type: EXPERIMENTAL
Intervention: Sarilumab 150 mg every 2 weeks (q2w)
Number of subjects: 0
Study 27716324 — intervention group
Group type: EXPERIMENTAL
Intervention: Sarilumab 200 mg every 2 weeks (q2w)
Number of subjects: 0
Study 27716324 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus MTX
Number of subjects: 0
Study 24720102 — intervention group
Group type: EXPERIMENTAL
Intervention: Outpatient cardiologic rehabilitation (24 forty-minute training sessions, 2-3 times a week for about 3 months)
Number of subjects: 108
Study 24720102 — intervention group
Group type: COMPARATOR
Intervention: Control group (no rehabilitation)
Number of subjects: 108
Study 24388336 — intervention group
Group type: EXPERIMENTAL
Intervention: 16S rRNA PCR
Number of subjects: 706
Study 24388336 — intervention group
Group type: COMPARATOR
Intervention: Blood culture
Number of subjects: 706
Study 22731926 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet intervention for amphetamine-type stimulant problems
Number of subjects: 160
Study 22731926 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 160
Study 20967275 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking
Number of subjects: 993
Study 18056488 — intervention group
Group type: EXPERIMENTAL
Intervention: Early passive mobilization (within three days after the fracture)
Number of subjects: 74
Study 18056488 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment (three-week immobilization followed by physiotherapy)
Number of subjects: 74
Study 16127964 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine 5 mg daily (adjusted to a maximum of 20 mg daily)
Number of subjects: 18
Study 16127964 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol 2 mg daily (adjusted to a maximum of 20 mg daily)
Number of subjects: 18
Study 12131428 — intervention group
Group type: EXPERIMENTAL
Intervention: Provocative discography screening (Group B)
Number of subjects: 73
Study 12131428 — intervention group
Group type: COMPARATOR
Intervention: No provocative discography screening (Group A)
Number of subjects: 73
Study 10403589 — intervention group
Group type: EXPERIMENTAL
Intervention: Single booster vaccination (day 0)
Number of subjects: 618
Study 10403589 — intervention group
Group type: EXPERIMENTAL
Intervention: Two booster vaccinations (day 0, 28)
Number of subjects: 618
Study 10403589 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 618
Study 8968528 — intervention group
Group type: EXPERIMENTAL
Intervention: Deflazacort 3 mg
Number of subjects: 24
Study 8968528 — intervention group
Group type: EXPERIMENTAL
Intervention: Deflazacort 6 mg
Number of subjects: 24
Study 8968528 — intervention group
Group type: EXPERIMENTAL
Intervention: Deflazacort 36 mg
Number of subjects: 24
Study 1424032 — intervention group
Group type: EXPERIMENTAL
Intervention: EPOCH 3,000 IU
Number of subjects: 205
Study 1424032 — intervention group
Group type: EXPERIMENTAL
Intervention: EPOCH 6,000 IU
Number of subjects: 205
Study 1424032 — intervention group
Group type: EXPERIMENTAL
Intervention: EPOCH 9,000 IU
Number of subjects: 205
Study 1424032 — intervention group
Group type: EXPERIMENTAL
Intervention: EPOCH (any dose) with ABP
Number of subjects: 205
Study 1424032 — intervention group
Group type: COMPARATOR
Intervention: Control (no EPOCH, no ABP)
Number of subjects: 205
Study 4051446 — intervention group
Group type: EXPERIMENTAL
Intervention: Proximal gastric vagotomy
Number of subjects: 52
Study 4051446 — intervention group
Group type: COMPARATOR
Intervention: Antrectomy
Number of subjects: 52